- See a full list of publications
- Browse activities and projects
- Explore connections, collaborators, related work and more
Charles Lacey is Professor of Medicine at Hull York Medical School (HYMS), and Honorary Consultant Physician in GU/HIV Medicine at York Hospitals Foundation Trust. He qualified from Guy’s Hospital Medical School, University of London, and undertook postgraduate training in Bristol, Bath, Cambridge, and Oman. He was appointed Consultant Physician in Genitourinary Medicine at the Leeds General Infirmary in 1982, and there developed his interest in sexually transmitted disease research, being awarded grants from the YCRC and MRC to study HPV and candidosis. He also led and advised on HPV and HSV vaccine development in collaboration with industry. In 1996 he was appointed Senior Lecturer in Genitourinary Medicine & Communicable Diseases at Imperial College London, and Honorary Consultant Physician, St Mary’s Hospital, London. He worked in Jonathan Weber’s group, both on HPV clinical and laboratory studies, and also developed a vaginal microbicide research programme, gaining funding from MRC, EC & NIH. In 2004 he moved to HYMS, initially as Reader, and then was appointed to the first Chair in clinical medicine in York in 2007.
Professor Charles Lacey's group conducts phase 1 clinical trials of mucosal vaccines and microbicides against HIV-1. The group is funded by awards from the Bill and Melinda Gates Foundation, the Wellcome Trust, the European Commission, and the NIH. As part of a Gates Grand Challenges award the group are conducting a phase 1 trial of a novel HIV vaginal vaccine utilising ZM96gp140, in conjunction with the Vaccine Institute, St George's, University of London. This is testing whether local mucosal and systemic immune responses can be generated in response to 9 immunisations with the gp140 into the female genital tract. The group has a number of other projects investigating genital tract immunology, including testing for Hepatitis B surface antigen-specific mucosal and systemic IgA and IgG responses, and aspects of genital tract Chlamydia immunology. Future projects include an investigation of whether the neonatal Fc receptor for IgG (FcRn), which has been shown to play a major role in regulating host IgG levels and transporting IgG and associated antigens across polarized epithelial barriers, is expressed in vaginal, ectocervical, endocervical, & endometrial tissues in healthy women.
As part of a Gates Grand Challenges award the group completed a phase 1 trial of a novel HIV vaginal vaccine utilising CN54gp140, in conjunction with St George's, University of London (SGUL). The MUCOVAC 1 trial investigated whether local mucosal and systemic immune responses can be generated in response to 9 immunisations of gp140 into the female genital tract.
MUCOVAC 2 is an exploratory phase 1 trial of three immunisations with CN54gp140 vaccine formulations administered through the intramuscular, intranasal and intravaginal routes in a variety of combinations. The study is in collaboration with SGUL and the Medical Research Council (MRC) Clinical Trials Unit (CTU). The project is funded by the Bill & Melinda Gates Foundation and the Wellcome Trust under the Grand Challenges in Global Health initiative and the UK HIV Vaccine Consortium.
Funded by the European Commission EUROPRISE programme, the study assesses the safety and pharmacokinetics of C2F5, C2G12, and C4E10 monoclonal antibodies when administered together in a gel vehicle as a vaginal microbicide. Participants receive vaginal microbicide gels containing either (a) high-dose monoclonal antibodies (b) low dose monoclonal antibodies, or (c) a control placebo vaginal microbicide gel.
This is a study looking at aspects of Chlamydia immunopathogenesis, in particular local and systemic antibody responses to C. trachomatis infection in women, and explores the correlation between antibody responses and load of C. trachomatis.
This project is in collaboration with the Kaye and Smith groups in CII investigating the development of a therapeutic CD8+ T cell-biased vaccine for visceral leishmaniasis. A new adenovirus-based vaccine is being developed, which will be taken into a phase 1 trial to assess safety and immunogenicity in York in 2011.
This is an MRC multicentre trial funded by the NHS R&D Health Technology Assessment (HTA) programme, UK. It is and RCT which compares switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients.
This is a study investigating mechanisms of immunoglobulin transport within the female genital tract. It is investigating whether FcRn is expressed and functional in the vagina, cervix, and endometrium. Such knowledge can be proposed as central to the goals of HIV vaccine development.
This is a European Commission Framework 7 research programme, studying Combination Highly Active Anti-Retroviral Microbicides. Within a large research programme, the Lacey groups and other partners from CHAARM will develop a combination ARV microbicide gel, and take this into a phase 1 trial.